Combining Aromatase Inhibitors, Bisphosphonates May Benefit Women With Breast Cancer

Share this content:
The use of combination aromatase inhibitors with bisphosphonates could help reduce breast cancer mortality in postmenopausal women.
The use of combination aromatase inhibitors with bisphosphonates could help reduce breast cancer mortality in postmenopausal women.

Two large meta-analyses suggest that combined aromatase inhibitors (AIs) and bisphosphonates may significantly improve survival prospects for postmenopausal women with early breast cancer.

The two studies, which have been published in The Lancet, found that by combining the two agents, there may be an increase in benefits and a decrease in side effects.

The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) is a worldwide collaboration established 30 years ago by researchers at the University of Oxford, Oxford, UK, to bring together every few years all the evidence from randomized trials on the treatment of early breast cancer.

The two reports, published July, 24 2015, provide the best evidence yet for the effects of AIs and bisphosphonates on postmenopausal women with early breast cancer.

The first study involved meta-analyses of individual data on 31,920 postmenopausal women with estrogen-receptor positive early breast cancer in the randomized trials of 5 years of AIs versus 5 years of tamoxifen.1

Compared to tamoxifen, taking AIs for 5 years further reduced the likelihood of the cancer recurring by approximately 30% and the risk of dying from breast cancer by 15% throughout the decade after beginning treatment.

The researchers estimated that compared with no endocrine treatment, the risk of dying from breast cancer for women who took AIs would be reduced by around 40% within 10 years after treatment initiation.

RELATED: Internal Mammary, Medial Supraclavicular Irradiation in Breast Cancer Evaluated

The second analysis examined data on 18,766 women in trials of 2 to 5 years of bisphosphonate therapy and a median follow-up of 5 to 6 woman-years.2

Bisphosphonates alter the bone microenvironment, which could make it less favorable for cancer cells and so reduce the risk of cancer recurrence in the bone and in other organs. However, previous clinical trials of bisphosphonates in early breast cancer have shown mixed results.

In the overall study population, the analyses showed that the only clear benefit of bisphosphonates was a 17% reduction in recurrence of cancer in the bone.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters